ReAlta Life Sciences doses first patient in trial of graft-versus-host disease drug

ReAlta Life Sciences doses first patient in trial of graft-versus-host disease drug

Submitted by admin on September 24, 2024 - 9:56pm
Source: 
Clinical Trials Arena
News Tags: 
ReAlta Life Sciences
RLS-0071
graft vs host disease
clinical trials
Headline: 
ReAlta Life Sciences doses first patient in trial of graft-versus-host disease drug
snippet: 

US-based biopharmaceutical company ReAlta Life Sciences has dosed the first subject in its Phase II clinical trial of RLS-0071 for treating steroid-refractory acute graft-versus-host disease (aGvHD).

Do Not Allow Advertisers to Use My Personal information